(Health) Amgen Announces KRAS Safety Update To U.S. Prescribing Information For Vectibix(R) (Panitumumab)
Amgen Inc. (Nasdaq: AMGN) announced the U.S. Food and Drug Administration (FDA) has approved revisions to the U.S. prescribing information for the epidermal growth factor receptor (EGFr) class of antibodies, including Vectibix((R)) (panitumumab).
Read more ...
Tags (health, health issue, health news, health care, medicine, medical innovation, health problem)
